BrightHeart
31.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
PARIS, FRANCE / ACCESSWIRE / May 31, 2023 / BrightHeart, a Paris-based medical technology company developing unique artificial intelligence software focused on improving the detection of congenital heart defects in fetuses, announced today that it has raised €2 million in seed financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan. The funds are being deployed to bolster the development of the BrightHeart technology, prepare its regulatory submission(s), and facilitate the company's expansion.
Combined with unique access to a proprietary database of more than 20,000 fetal ultrasound exams, BrightHeart's innovative technology leverages AI and top-level expertise in fetal ultrasound cardiac imaging to help caregivers improve the detection of complex fetal heart defects in utero, during an ultrasound screening exam, when early interventions could either correct them or greatly improve a child's chance of survival. This is the fourth investment by Sofinnova's medtech acceleration fund, Sofinnova MD Start III.
Cécile Dupont, BrightHeart's Chief Executive Officer and Partner at Sofinnova Partners, said:" Fetal ultrasound screening of the heart is universally recommended during pregnancy. Prenatal diagnosis of fetal heart defects can significantly improve newborn outcomes, but in practice, as few as 30% are detected. BrightHeart's unique, AI-powered approach has the potential to revolutionize screening for congenital heart defects by supporting clinicians with a real-time, expert-level interpretation of one of the most complex exams in the ultrasound practice."
BrightHeart has already brought together an experienced team in the fields of fetal cardiology, AI, and software development. This unique group is led by Chief Technology Officer Christophe Gardella, an accomplished data scientist and leader with extensive experience in the development of AI-powered medtech solutions who directed the algorithm efforts at Cardiologs.
Inspired by the company's mission, the multidisciplinary team has made remarkable progress. Just a few months after its inception, the company is already finalizing a first version of its software, filed multiple patent applications in Europe and the U.S., engaged with regulators, and is actively working on the preparation of regulatory submissions for its first product in key geographies.
BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, BrightHeart co-founders, fetal cardiologists, and leading experts in the sector. They bring a world-class expertise to the project as well as a large, qualified database of fetal heart ultrasound exams.
In a joint statement, Drs. Levy and Stos said: "BrightHeart's innovative approach addresses a major critical need. We are thrilled to count on operational, strategic, and financial support from Sofinnova MD Start III in this important commitment to accelerate the deployment of our technology in the clinic, and to improve maternal and fetal health."
About BrightHeart
BrightHeart SAS is a Paris-based, privately held, pre-clinical medical device company and part of Sofinnova MD Start, the venture capital firm's medical device accelerator. The company's software leverages the power of artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve newborn outcomes by anticipating delivery care and early intervention.
BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, two leading fetal cardiologists based in Paris, France.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com.
For further information:
Cécile Dupont
Chief Executive Officer, BrightHeart
cecile@brightheart.fr
SOURCE: BrightHeart
View source version on accesswire.com:
https://www.accesswire.com/758073/BrightHeart-Announces-2-Million-in-Seed-Financing-from-Sofinnova-Partners-to-Improve-the-Detection-of-Fetal-Heart-Abnormalities
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY and Zip US Introduce Unified Trust Layer Framework to Help Merchants Reduce Risk in Agentic Commerce24.3.2026 11:00:00 CET | Press release
Open, Collaborative Initiative to Establish Identity, Preserve Intent, and Make Trust Measurable in AI-Initiated Commerce LEHI, UT AND NEW YORK, NY / ACCESS Newswire / March 24, 2026 / IXOPAY, the enterprise-grade global payment infrastructure platform built for the era of agentic commerce, and Zip, the digital financial services company offering innovative, people-centred products, today announced a joint initiative to define a Unified Trust Layer - an open industry framework designed to address emerging trust and liability challenges in agent-initiated commerce and payments. Agentic commerce introduces a structural shift in payments. Traditional infrastructure was built around a four-party risk model - consumer, merchant, issuing bank, and acquiring bank - with the assumption that a human initiated the transaction. As AI agents begin acting autonomously, that model no longer holds. Payment systems were not designed to consistently preserve identity, intent, and context in a machine-v
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries23.3.2026 16:15:00 CET | Press release
OMP, a global leader in AI-powered supply chain planning solutions, has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions: Process Industries, positioned highest for both "Completeness of Vision" and "Ability to Execute". ANTWERPEN, BE / ACCESS Newswire / March 23, 2026 / This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time. Advancing intelligent planning for the most complex supply chain needs Trusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders23.3.2026 14:05:00 CET | Press release
TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, impr
Xypex 2025 International Best Project Awards - Winners Announced19.3.2026 21:00:00 CET | Press release
Xypex announces 2025 award winners recognizing excellence in concrete durability, engineering performance, and crystalline waterproofing technology. VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / Xypex announces the winners of the 2025 International Best Project Awards, recognizing construction projects that demonstrate excellence in concrete durability, engineering performance, and the use of crystalline waterproofing technology. This year's program received more than 80 project submissions from over 20 countries across five continents, reflecting the global reach of Xypex technology and the strength of its international network of distributors, engineers, contractors, and partners. The submissions represented a broad range of projects across infrastructure, general construction, water and wastewater facilities, industrial structures, and small-scale applications. Projects were evaluated based on engineering complexity, construction challenges, durability requirements, and the int
Brookville DMAX Expansion Highlights the Project Work Behind a Major Ohio Manufacturing Investment19.3.2026 16:00:00 CET | Press release
BROOKVILLE, OH / ACCESS Newswire / March 19, 2026 / General Motors' Duramax Engine Plant (DMAX) expansion in Brookville has become one of the region's most significant industrial projects, tied to a $920 million investment supporting Duramax diesel engine production for GM heavy-duty truck programs, including Chevrolet Silverado HD and GMC Sierra HD models. Public reporting has described the Brookville work as adding about 1.1 million square feet to the existing facility which was previously approximately 250,000 square feet. Notably, the project has created and supported hundreds of local jobs as the site expands its manufacturing footprint in southwest Ohio. This expansion quadruples the current facility size and is designed to create over 800 jobs, supporting high demand for diesel trucks. Among the professionals helping carry that work forward is Sabra Sadeghi, a project architect and engineer who served on the Brookville expansion in an on-site role. The project has been praised f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom